New azolidinediones as inhibitors of protein tyrosine phosphatase lb with antihyperglycemic properties

Journal of Medicinal Chemistry

Volumn 43, Issue 5, 2000, Pages 995-1010

  Malamas, Michael S ^a   Sredy, Janet ^a,b   Gunawan, Iwan ^a   Mihan, Brenda ^a   Sawicki, Diane R ^a,b   Seestaller, Laura ^a   Sullivan, Donald ^a   Flam, Brenda R ^a  

^a PFIZER INC   (United States)

^b The Institute for Diabetes Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CIGLITAZONE; GLUCOSE; INSULIN; OXADIAZOLE DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DIABETES MELLITUS; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIVER MEMBRANE; MALE; MOUSE; NONHUMAN; RAT;

4-NITROPHENYLPHOSPHATASE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; MALE; MEMBRANE PROTEINS; MICE; MICE, OBESE; OXAZOLES; PROTEIN-TYROSINE-PHOSPHATASE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034624722     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990476x     Document Type: Article

References (49)

1. DeFronzo, R. A.; Bonadonna, R. C.; Ferrannini, E. Pathogenesis of NIDDM. Diabetes Care 1992, 15, 318-368.
2. Reaven, G.; Bernstein, R.; Davis, B.; Olefsky, J. M. Nonketonic Diabetes Mellitus: Insulin Deficiency or Insulin Resistance? Am. J. Med. 1976, 60, 80.
3. Reaven, G. Role of Insulin Resistance in Human Disease. Diabetes 1988, 37, 1595-1607.
4. (a) Goldman, J. M. Oral Hypoglycemic Agents: An Update of Sulfonylureas. Drugs Today 1989, 25, 689-695.
5. (b) Kolterman, O. G.; Prince, M. J.; Olefsky, J. M. Insulin Resistance in Non-Insulin Dependent Diabetes Mellitus. Impact of sulfonylureas agents in vivo and in vitro. Am. J. Med. 1983, 74 (Suppl. 1A), 82-101.
6. (c) Ferrannini, E. The Insulin resistance Syndrome. Curr. Opin. Nephrol. Hypertens. 1992, 1, 291-298.
7. Sohda, T.; Mizuno, K.; Tawada, H.; Sugiyama, Y.; Fujita, T.; Kawanatsu, Y. Studies on Antidiabetic agents II. Synthesis of 5[4-(1-Methylcyclohexylmethoxy)benzyl]thiazolidine-2,4-dione and its Derivatives. Chem Pharm. Bull. 1982, 30, 3563-3573, 3580-3600.
8. (a) Fujiwara, T.; Yoshioka, S.; Yoshioka, Y,; Ushiyama, I.; Horikishi, H. Characterization of New Oral Antidiabetic Agent CS-045. Diabetes 1988, 37, 1549-1558.
9. (b) Momose, Y.; Meguro, K.; Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Studies on Antidiabetic Agents: Synthesis and Biological Activities of Pioglitazone and Related Compounds. Chem. Pharm. Bull. 1991, 39, 1440-1445.
10. (c) Dow, R. L.; Bechle, B. M.; Chou T. T.; Clark, D. A.; Hulin, B.; Stevenson, R. W. Benzyloxazolidine-2,4-diones as Potent Hypoglycemic Agents. J. Med. Chem. 1991, 34, 1538-1544.
11. (d) Clark, D. A.; Goldstein S. W.; Volkmann, R. A.; Eggler, J. F.; Holland, G. F.; Hulin, B.; Stevenson, R. W.; Kreutter, D. K.; Gibbs, E. M.; Krupp, M. N.; Merrigan, P.; Kelbaugh, P. L.; Andrews, E. G.; Tickner, D. L.; Suleske, R. T.; Lamphere, C. H.; Rajeckas, F. J.; Kappeler, W. H.; McDermott, R. E.; Hutson, N. J.; Johnson, M. R. Substituted Dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents. J. Med. Chem. 1991, 34, 319-325.
12. (e) Hulin, B.; Clark, D. A.; Goldstein, S. W.; McDermott, R. E.; Dambek, P. J.; Kappeler, W. H.; Lamphere, C. H.; Lewis, D, M.; Rizzi, J. P. Novel Thiazolidine-2,4-diones as potent Euglycemic agents. J. Med. Chem. 1992, 35, 1853-1864.
13. (f) Goldstein, S. W.; McDermott, R. E.; Gibbs, E. M.; Stevenson, R. W. Hydroxyurea Derivatives as Hypoglycemic Agents. J. Med. Chem. 1993, 36, 2238-2240.
14. (g) Cantello, B. C.; Cawthorne, M. A.; Haigh, D.; Hindley, R. M.; Smith, S. A.; Thurlby, P. L. The synthesis of BRL-49653 -A Novel and Potent Antihyperglycemic agent. Bioorg. Med. Chem. Lett. 1994, 4, 1181-1184.
15. (h) Cantello, B. C.; Cawthorne, M. A.; Cottam, G. O.; Duff, P. T.; Haigh, D.; Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurrlby, P. L. [[ω-(Heterocycloamino)alkoxy]banzyl]-2,4-thiazolidinediones as Potent Antihyperglycemic Agents. J. Med. Chem. 1994, 37, 3977-3985.
16. (i) Reddy, K. A.; Lohray, B. B.; Bhushan, V.; Bajji, A. C.; Reddy, K. V.; Reddy, P. R.; Krishna, T. H.; Rao, I. N.; Jajoo, H. K.; Rao, N. V.; Chakrabarti, R.; Dileepkumar, T.; Rajagopalan, R. Novel and Hypolipidemic Agents. 3. Benzofuran-Containing Thiazolidinediones. J. Med. Chem. 1999, 42, 1927-1940.
17. (a) Matsumoto, K.; Miyake, S.; Yano, M.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749. Additional information in Scrips 1997, 2282, 21, and Scrips 1997, 2292, 20.
18. (a) Matsumoto, K.; Miyake, S.; Yano, M.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749. Additional information in Scrips 1997, 2282, 21, and Scrips 1997, 2292, 20.
19. (a) Matsumoto, K.; Miyake, S.; Yano, M.; Tominaga, Y. Increase of Lipoprotein (a) with Troglitazone. Lancet 1997, 350, 1748-1749. Additional information in Scrips 1997, 2282, 21, and Scrips 1997, 2292, 20.
20. (b) Troglitazone is being marketed in the United States as Rezulin and in Japan as Noscal.
21. Haring, H. U. The Insulin Receptor: Signaling Mechanism and Contribution to the Pathogenesis of Insulin Resistance. Diabetalogia 1991, 34, 848.
22. Goldstein, B J. Protein-Tyrosine Phosphatases and the Regulation of Insulin Action. J. Cell. Biochem, 1992, 31, 33-42. Goldstein, B. J. Regulation of Insulin Receptor Signaling by Protein-Tyrosine Dephosphorylation. Receptor 1993, 3, 1-15. Ahmad, F.; Goldstein, B. J. Purification, Identification and Subcellular Distribution of Three Predominant Protein-Tyrosine Phosphatase Enzymes in Skeletal Muscle Tissue. Biochim. Biophys. Acta 1995, 1248, 57-69.
23. Goldstein, B J. Protein-Tyrosine Phosphatases and the Regulation of Insulin Action. J. Cell. Biochem, 1992, 31, 33-42. Goldstein, B. J. Regulation of Insulin Receptor Signaling by Protein-Tyrosine Dephosphorylation. Receptor 1993, 3, 1-15. Ahmad, F.; Goldstein, B. J. Purification, Identification and Subcellular Distribution of Three Predominant Protein-Tyrosine Phosphatase Enzymes in Skeletal Muscle Tissue. Biochim. Biophys. Acta 1995, 1248, 57-69.
24. Goldstein, B J. Protein-Tyrosine Phosphatases and the Regulation of Insulin Action. J. Cell. Biochem, 1992, 31, 33-42. Goldstein, B. J. Regulation of Insulin Receptor Signaling by Protein-Tyrosine Dephosphorylation. Receptor 1993, 3, 1-15. Ahmad, F.; Goldstein, B. J. Purification, Identification and Subcellular Distribution of Three Predominant Protein-Tyrosine Phosphatase Enzymes in Skeletal Muscle Tissue. Biochim. Biophys. Acta 1995, 1248, 57-69.
25. McGuire M. C.; Fields, R. M.; Nyomba, B. L.; Raz, I.; Bogardus, C.; Tonks, N. K.; Sommercorn, J. Abnormal Regulation of Protein Tyrosine Phosphatase Activities in Skeletal Muscle of Insulin-Resistant Humans. Diabetes 1991, 40, 939.
26. Myerovitch, J.; Baker, J. M.; Kahn, C. R. Hepatic Phosphatyrosine Phosphatase Activity and Its Alterations in Diabetic Rats. J. Clin. Invest. 1989, 84, 976.
27. Sredy, J.; Sawicki, D. R.; Flam, B. R.; Sullivan, D. Insulin Resistance Is Associated With Abnormal Dephosphorylation of a Synthetic Phosphopeptide Corresponding to the Major Autophosphorylation Sites of the Insulin Receptor. Metabolism 1995, 44, 1074.
28. (a) Evans, J. L.; Jallal, B. Protein Tyrosine Phosphatases: Their Role in Insulin Action and Potential Drug Targets. Exp. Opin. Invest. Drugs 1999, 8, 139-160.
29. (b) Brichard, S. M.; Bailey, C. J.; Henquin, J. C. Vanadate Improves Glucose Homeostasis in Insulin-Resistant ob/ob Mice. Fundam. Clin. Pharmacol. 1990, 4, 54S.
30. Cro, G.; Serrano J. J.; Mongold, J. J.; Tep, A.; Vian, L.; Lazaro, R. Effects of Vanadyl Derivatives on Animal Models of Diabetes. Fundam. Clin. Pharmacol. 1990, 4, 20S.
31. Byon, J. C. H.; Kusari, A. B.; Kusari, J. Protein-Tyrosine Phosphatase-1B Acts as a Negative Regulator of Insulin Signal Transduction. Mol. Cell Biochem. 1998, 182, 101-108.
32. Elchebly, M.; Payette, P.; Michaliszyn, E.; Cromlish, W.; Collins, S.; Loy, A. L.; Normandin, D.; Cheng, A.; Himms-Hagen, J.; Chan, C. C.; Ramachandran, C.; Gresser, M. J.; Tremblay, M. L.; Kennedy, B. P. Increased Insulin Sensitivity and Obesity Resistance in Mice Lacking the Protein Tyrosine Phosphatase-1B. Science 1999, 283, 1544-1548.
33. Meguro, K.; Fugita, T. Thiazolidinedione Derivatives; Their Production and Use. Eur. Patent 177353, 1986.
34. Hughes, D. L. The Mitsunobu Reaction. Organic Reactions; John Wiley & Sons Publishers: New York, 1992; pp 335-656.
35. (a) Horner, L.; Hoffman, H.; Wippel, H. G.; Klahre, G. Chem. Ber. 1959, 92, 2499.
36. (b) Wadsworth, W. S.; Emmons, W. D. J. Am. Chem. Soc. 1961, 83, 1733.
37. Turchi, I. J. Oxazoles. Heterocyclic Compounds; John Wiley & Sons Publishers: New York, 1986; pp 1-341.
38. Tawada, H.; Nakata, F.; Sugiyama, Y.; Fujita, T.; Meguro, K. Syntheses and Antidiabetic Activity of 1,2,4-Oxadiazole Derivatives. J. Takeda Res. Lab. 1984, 43, 1-11.
39. Borden, W. T. The Mechanism of Hydride Attack in the Reduction of trans-1-tert-Butyl-3-phenylallyl and 1-tert-Butyl-3-phenylpropargyl Alcohols. J. Am. Chem. Soc. 1970, 92, 4898.
40. Barford, D. P.; Keller, J. C.; Flint, A. J.; Tonks, N. K. Purification and Crystallization of the Catalytic Domain of Human Protein Tyrosine Phosphatase 1B Expressed in Escherichia coli. J. Mol. Biol. 1994, 239, 726-730.
41. Goldstein, B. J.; Zhang, W.; Hashimoto, N.; Kahn, C. R. Approaches to The Molecular Cloning of Protein Tyrosine Phosphatases in Insulin Sensitive Tissues. Mol. Cell. Biochem. 1992, 109, 107-113.
42. Lanzetta, P. A.; Alvarez, L. J.; Reinach, P. S.; Candia, O. A.; An Improved Assay for Nanomolar Amounts of Inorganic Phosphate. Anal. Biochem. 1979, 100, 95-97.
43. Meyerovitch, J.; Rothenberg, P.; Shechter, Y.; Bonner-Weir, S.; Kahn, C. R. Vanadate Normalizes Hyperglycemia in Two Mouse Models of Non-Insulin-Dependent Diabetes Mellitus. J. Clin. Invest. 1991, 87, 1286-1294.
44. Moss, D. W. Acid phosphatases. In Methods of Enzymatic Analysis, 3rd ed.; Bergmeyer, H. U., Ed.; Verlag Chemie GmbH: Germany, 1984; Vol. IV, Chapter 1.6, pp 92-106.
45. Tonks, N. K.; Diltz, C. D.; Fischer, E. H. Characterization of The Major Protein-Tyrosine-Phosphatases of Human Placenta. J. Biol. Chem. 1988, 263, 6731-6737.
46. Wrobel, J.; Li, Z.; Dietrich, A.; McCaleb, M.; Mihan, B.; Sredy, J.; Sullivan, D. Novel 5-(3-Aryl-2-propynyl)-5-(arylsulfonyl)-thiazolidine-2,4-diones as Antihyperglycemic Agents. J. Med. Chem. 1998, 41, 1084-1091.
47. Ramachandran, C.; Aebersold, R.; Tonks, N. K.; Pot, D. A. Sequential Dephosphorylation of a Multiple Phosphorylated Insulin Receptor Peptide by Protein Tyrosine Phosphatases. Biochemistry 1992, 31, 4232-4238.
48. Flam, B. R.; Sawicki, D. R.; Sredy, J. The Use of Phosphotyrosyl Peptides and pNPP to Assess PTPase Activity in Tissues from Diabetic Rodents. FASEB J. 1994, 8, S68.
49. Lehman, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkinson, W. O.; Kliewer, S. A. An Antidiabetic Thiazolidinedione is a High Affinity Ligands for Peroxisome Proliferator-activated Receptor γ (PPARγ). J. Biol. Chem. 1995, 270, 12953-12956.